Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesKalaris Therapeutics, Inc.

Kalaris Therapeutics, Inc.

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
2.02 USD -0.03 ( 1.46%)
Last update at 2026-11-04T21:00:00Z
VOLUME
28255
Market Cap
76.18M

Momentum Score

…

Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was founded in 2019 and is headquartered in Berkeley Heights, New Jersey.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
2.01
Low
2.14
High
52 Week Price Range
3.03
Low
11.88
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
2.05
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.02
ROE
-79.91%
Net Debt
-96.61M
ROCE
-37.49%
Diluted EPS TTM
-1.90

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -43.44M -58.77M -14.70M -15.48M -170.96M
Net income -43.44M -58.77M -14.70M -15.48M -171.96M
Selling general administrative 15.40M 6.69M 1.76M 2.24M -
Gross profit -0.01M - - - -1.12M
Reconciled depreciation 0.01M 0.00M - - -
Ebit -41.99M - -13.46M -14.01M -170.96M
Ebitda -41.98M -58.77M -14.01M -15.25M -169.84M
Depreciation and amortization 0.01M - - - 1.12M
Operating income -46.15M -55.26M -13.46M -14.01M -169.82M
Other operating expenses 46.15M 55.26M 13.46M 14.01M 169.82M
Interest expense 1.44M 2.70M 0.69M 0.23M -
Net interest income -1.44M -2.70M -0.69M -0.23M -
Income tax expense - - - - 1.01M
Total revenue 0.00M 0.00M 0.00M 0.00M -
Total operating expenses 46.14M 55.26M 13.46M 14.01M 168.70M
Cost of revenue 0.01M - - - 1.12M
Total other income expense net 2.71M -3.51M -1.24M -1.48M -1.14M
Net income from continuing ops -43.44M -69.17M -14.70M -15.48M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 121.74M 118.55M 3.33M 3.90M 286.59M
Other current assets 0.83M 0.26M 0.16M 0.84M 5.18M
Total liab 42.92M 5.24M 48.35M 34.17M 61.33M
Total stockholder equity 78.81M 113.31M -45.02M -30.27M 225.27M
Other current liab 8.12M 4.99M 1.58M 2.93M 22.90M
Common stock 0.00M - - - 0.01M
Capital stock 0.00M 0.00M 0.00M 0.00M -
Retained earnings -160.00M -714.96M -47.39M -32.70M -297.06M
Cash 98.05M 118.29M 3.17M 3.06M 201.66M
Total current liabilities 9.71M 5.24M 3.94M 5.69M 37.85M
Net debt -96.61M -118.29M -3.17M 0.19M -171.59M
Short term debt 0.32M - - - 6.59M
Short long term debt - 19.54M - - -
Short long term debt total 1.45M - - 3.25M 30.07M
Other stockholder equity 238.81M 828.40M 2.38M 2.42M 522.48M
Total current assets 118.81M 118.55M 3.33M 3.90M 253.35M
Short term investments 19.93M 0.00M - - 46.46M
Net receivables - - - - 0.05M
Long term debt - - - 3.25M -
Accounts payable 1.28M 0.25M 2.36M 2.76M 8.36M
Accumulated other comprehensive income 0.01M -0.14M - - -0.15M
Non currrent assets other 0.95M 0.41M - - 1.10M
Non current assets total 2.93M 3.56M 0.00M 0.00M 33.25M
Capital lease obligations 1.45M 0.00M - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -19.52M 0.00M - - -
Total cashflows from investing activities -19.72M 95.00M - - 185.98M
Net borrowings 7.50M 19.97M 6.00M 4.30M -
Total cash from financing activities 159.61M 0.02M 14.24M 12.78M 0.23M
Net income -43.44M -58.77M -14.70M -15.48M -171.96M
Change in cash -20.23M 28.17M 0.11M 3.00M 79.00M
Begin period cash flow 118.29M 90.12M 3.06M 0.06M 122.66M
End period cash flow 98.05M 118.29M 3.17M 3.06M 201.66M
Total cash from operating activities -42.98M -67.70M -14.13M -9.78M -106.32M
Issuance of capital stock 42.00M 1.59M 6.74M 8.47M -
Depreciation 0.01M 0.00M - - 1.12M
Change to account receivables - 0.21M - - 0.40M
Other cashflows from financing activities 102.11M - 8.24M 8.48M -
Capital expenditures 0.20M 0.00M 0.00M 0.00M 0.03M
Change in working capital 3.43M -25.30M -1.09M 3.40M 19.35M
Stock based compensation 1.94M 0.90M 0.15M 0.27M -
Other non cash items -2.98M 16.37M 1.51M 2.04M 45.17M
Free cash flow -43.18M -67.70M -14.13M -9.78M -106.34M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
KLRS
Kalaris Therapeutics, Inc.		 -0.03
1.46%		 2.02 - - - 1.36
NVO
Novo Nordisk A/S		 1.99
4.95%		 42.18 41.58 31.15 2.13 32.99
VRTX
Vertex Pharmaceuticals Inc		 18.28
3.44%		 549.04 30.22 24.27 10.36 6.50
REGN
Regeneron Pharmaceuticals Inc		 -41.91
4.31%		 931.45 29.07 20.12 7.57 3.82
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12

Profile*

Kalaris Therapeutics, Inc.

Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was founded in 2019 and is headquartered in Berkeley Heights, New Jersey.

400 Connell Drive, Berkeley Heights, NJ, United States, 07922

650 249 2727

https://kalaristx.com

20

Name Title Year Born
Mr. Andrew Oxtoby President, CEO & Director 1974
Dr. Srinivas Akkaraju M.D., Ph.D. Director & Co-Founder 1968
Dr. Michael Philip Dybbs Ph.D. Co-Founder & Director 1975
Dr. Napoleone Ferrara M.D. Independent Director & Co-Founder 1957
Dr. Matthew Feinsod M.D. Chief Medical Officer 1971
Ms. Liisa Ann Bayko M.B.A. CFO & Treasurer 1971
Ms. Amy Vandekop Interim Principal Accounting Officer & Corporate Controller 1989
Ms. Kristine Curtiss Senior Vice President of Clinical NA
Dr. Jill E. Porter Ph.D. Senior Vice President of CMC NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PRL
CAD 30.50
+15.05%
DSV
CAD 11.02
+14.55%
USA
CAD 4.29
+13.19%
NUAG
CAD 7.70
+12.90%
GMIN
CAD 43.79
+12.86%
DRUG
CAD 26.11
-29.58%
HUT
CAD 68.98
-22.41%
UCU
CAD 2.09
-14.34%
VET
CAD 14.87
-14.29%
PHX
CAD 10.96
-13.56%

Equity Sectors*

  • Basic Materials

    +5.46%

  • Communication Services

    +3.38%

  • Consumer Cyclical

    +3.11%

  • Consumer Defensive

    +1.35%

  • Energy

    -4.79%

  • Financial Services

    +2.66%

  • Healthcare

    -0.72%

  • Industrials

    -0.11%

  • Real Estate

    +1.84%

  • Technology

    +1.05%

  • Utilities

    +0.39%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…